Cart is empty Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late breaking research presented in a Hot Line session August 28 at ESC Congress 2023.
Leave A Comment